Revised SPC: Epclusa (sofosbuvir, velpatasvir) 400mg/100mg film coated tablets

Section 4.8 has been updated to include new safety information on rash and angioedema following a cumulative review of hypersensitivity with Epclusa and Vosevi (sofosbuvir, velpatasvir and voxilaprevir), prompted by routine pharmacovigilance and signal detection activities.

Source:

electronic Medicines compendium